Search results
Results From The WOW.Com Content Network
By 20 October, Canada had pledged 65.4 million Canadian dollars to the fight against Ebola. As part of its contribution, Canada has deployed two mobile diagnostic laboratories in Sierra Leone, and shipped the first batch of an experimental Ebola vaccine to the WHO in Geneva.
A number of companies were expected to develop Ebola vaccines: GlaxoSmithKline, NewLink Genetics, Johnson & Johnson, and Bavarian Nordic. [82] Another company, Emergent BioSolutions, was a contestant for manufacturing new doses of ZMapp, [citation needed] a drug for Ebola virus disease treatment originally developed by Mapp Biopharmaceutical. [83]
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. [1] Symptoms typically start anywhere between two days and three weeks after infection. [3] The first symptoms are usually fever, sore throat, muscle pain, and headaches. [1]
The 2013–2016 epidemic of Ebola virus disease, centered in West Africa, was the most widespread outbreak of the disease in history.It caused major loss of life and socioeconomic disruption in the region, mainly in Guinea, Liberia and Sierra Leone.
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
Additionally, he was the chief of the Special Pathogens Unit at the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC) in Winnipeg, Manitoba, for eight years. [1] Kobinger is known for his critical role in the development of both an effective Ebola vaccine and treatment.
This was the most severe Ebola outbreak in recorded history in regards to both the number of human cases and fatalities. It began in Guéckédou , Guinea, in December 2013 and spread abroad. [ 37 ] [ 38 ] [ 33 ] Flare-ups of the disease continued into 2016, [ 39 ] and the outbreak was declared over on 9 June 2016.
Xiangguo Qiu (Chinese: 邱香果) is a Chinese Canadian virologist, former adjunct professor of Medical microbiology at the University of Manitoba and former head of the Vaccine Development and Antiviral Therapies section in the Special Pathogen Program of the Public Health Agency of Canada (PHAC).